E Fund Management Co. Ltd. boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 20.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,293 shares of the biotechnology company’s stock after acquiring an additional 2,647 shares during the period. E Fund Management […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,720,000 shares, a decrease of 13.0% from the January 15th total of 8,870,000 shares. Based on an average daily volume of 1,550,000 shares, […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Releases Earnings Results, Misses Expectations By $0 46 EPS themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Posts Earnings Results, Misses Expectations By $0 46 EPS theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its target price hoisted by analysts at Citigroup from $33.00 to $34.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s price objective would suggest a potential upside of 8.35% from the stock’s previous close. […]